Skip to main content

Day: August 30, 2024

Dundee Precious Metals Completes Sale of Tsumeb Smelter

TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or “the Company”) today announced the closing of the sale of the Tsumeb smelter to a subsidiary of Sinomine Resource Group Co. Ltd. (“Sinomine”). “In line with our strategy, the Tsumeb divestiture is another step in our continued track record of creating shareholder value. I’d like to extend our thanks to the government of Namibia, Sinomine and our former employees and stakeholders for its safe transition and continued success,” said David Rae, President and CEO. The purchase price for the sale of the Tsumeb smelter was US$20 million, on a debt-free and cash-free basis, less a US$5 million holdback to be held in escrow for a period of six months to secure the Company’s indemnity obligations under the share purchase agreement with Sinomine. Total...

Continue reading

FangDD Reports First Half 2024 Unaudited Financial Results

SHENZHEN, China, Aug. 30, 2024 (GLOBE NEWSWIRE) — Fangdd Network Group Ltd. (NASDAQ: DUO) (“FangDD” or “the Company”), a customer-oriented property technology company in China, today announced its unaudited financial results for the six months ended June 30, 2024. First Half 2024 Financial HighlightsRevenue for the six months ended June 30, 2024 slightly decreased by 8.8% to RMB140.0 million (US$19.3 million) from RMB153.5 million for the same period of 2023. Net income for the six months ended June 30, 2024 was RMB16.4 million (US$2.3 million), compared to net income of RMB9.4 million for the same period of 2023. Non-GAAP net income1 for the six months ended June 30, 2024 was RMB16.4 million (US$2.3 million), compared to non-GAAP net income of RMB9.4 million for the same period of 2023.First Half 2024 Operating Highlights...

Continue reading

Robex Reports Q2 2024 Results

QUEBEC CITY, Aug. 30, 2024 (GLOBE NEWSWIRE) — Robex Resources Inc. (“Robex” or the “Company“) (TSXV: RBX) today reports operational and financial results for the second quarter ending June 30th, 2024 (“Q2 2024“). HIGHLIGHTS STRATEGIC INITIATIVESManagement and Board change: The company announced a Management and Board change. The company is now lead by Matthew Wilcox (CEO and Director) and James Askew Non-Executive Chairman. The Board has been restructured and is composed of James Askew (Chairman of the Board), John Dorward, Howard Golden, Thomas Lagrée and Gérard de Hert (all non-executive directors), and Matthew Wilcox. Strategic initiative: The company announced a strategic decision to start a sale process for its Mali assets and its intention to relist on the ASX as a development company...

Continue reading

Announces Semi-Annual Results

TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) — — (TSX: TXT.UN; TXT.PR.A) — Top 10 Split Trust (the “Fund”) announces results of operations for the six months ended June 30, 2024. Decrease in net assets attributable to holders of Capital Units amounted to $0.13 million or $0.25 per Capital Unit. Net assets attributable to holders of Capital Units as at June 30, 2024 were $0.94 million or $1.88 per Capital Unit. Cash distributions of $0.39 per Preferred Security and $0.09 per Capital Unit were paid to securityholders during the period. The Fund’s investment objectives for the Capital Units are (i) to provide holders of Capital Units, upon redemption, with the benefit of any capital appreciation in the market price of the securities in the Financial Portfolio and (ii) to pay quarterly distributions to holders of Capital Units...

Continue reading

SAIC Board of Directors Declares Cash Dividend

RESTON, Va., Aug. 30, 2024 (GLOBE NEWSWIRE) — Science Applications International Corp. (NASDAQ: SAIC) announced today that the company’s board of directors declared a cash dividend of $0.37 per share of the company’s common stock payable on October 25, 2024 to stockholders of record on October 11, 2024. SAIC intends to continue paying dividends on a quarterly basis, although the declaration of any future dividends will be determined by the board of directors each quarter and will depend on earnings, financial condition, capital requirements and other factors. About SAIC SAIC® is a premier Fortune 500® technology integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, civilian and intelligence markets includes secure high-end...

Continue reading

Opthea Reports Full-Year Financial Results and Business Updates

Completed patient enrollment in COAST and ShORe pivotal wet AMD trials Financings extended cash runway through topline data readout of both trials in CY2025 Leadership appointments in preparation for regulatory filing and launch of sozinibercept MELBOURNE, Australia, and PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) —  Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced financial results for the twelve months ended June 30, 2024, and highlighted recent corporate and clinical updates. “During the 2024 fiscal year, we made outstanding progress in advancing sozinibercept’s Phase 3 wet AMD program,” said Frederic Guerard,...

Continue reading

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days. About CG OncologyCG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.